Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,160 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Azacitidine, Sargramostim
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acute Kidney Failure
Interventions
Furosemide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Conditions
Acute Graft-Versus-Host Disease, GIGVHD
Interventions
ALXN1007 10 mg/kg once weekly, ALXN1007 20 mg/kg once weekly, ALXN1007 20 mg/kg twice weekly
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Detroit, Michigan + 6 more
Completed Not applicable Interventional Results available

Heartfulness Meditation (HFM) in Cyclic Vomiting Syndrome (CVS)

NCT05961995
Conditions
Cyclic Vomiting Syndrome
Interventions
Heartfulness meditation
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Leukemia
Interventions
filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years to 69 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Paterson, New Jersey
Completed Phase 4 Interventional Results available

Ictal and Interictal Inflammatory Markers in Migraine

NCT01138150
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Leukemia
Interventions
CLAG Regimen, Gleevec®
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional Results available

Continuous Subpleural Infusion of Bupivacaine

NCT01566838
Conditions
Postoperative Pain
Interventions
Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Conditions
Peridialytic Hypotension
Interventions
Transpulmonary Thermodilution
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Biphenotypic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Migraine, Pain
Interventions
Nitrous Oxide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
8 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Lymphoblastic Leukemia, Hyperbilirubinemia
Interventions
Levocarnitine, Vitamin B Complex
Dietary Supplement · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Not listed Not applicable Interventional

RF Applications for Residual LAA Leaks

NCT04726943
Conditions
Left Atrial Appendage Thrombosis, Stroke, Ischemic, Atrial Fibrillation
Interventions
Radiofrequency Energy Applications
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Overland Park, Kansas • Austin, Texas
Conditions
Acute Pain
Interventions
VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 4 more
Conditions
Quality of Life
Interventions
Physical Activity
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2031
U.S. locations
1
States / cities
Hartford, Connecticut
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Conditions
Acute Coronary Syndrome, Fear Anxiety, Physical Inactivity
Interventions
Reducing Exercise Sensitivity with Exposure Training
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Pain, Postoperative
Interventions
Intravenous Diclofenac (DIC075V), Intravenous Ketorolac, placebo
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Florence, Alabama • Montgomery, Alabama + 11 more
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Acute Myeloid Leukemia
Interventions
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
30
States / cities
Scottsdale, Arizona • Bentonville, Arkansas • Los Angeles, California + 27 more
Conditions
Post-Acute COVID-19 Syndrome, Cognitive Dysfunction
Interventions
Pascal device, Sham Device
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
FT-2102 (olutasidenib), Azacitidine, Cytarabine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more
Conditions
Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Rupture
Interventions
Experimental Group, Control Group
Drug · Other
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
14 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Gulf Breeze, Florida